Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing

Jingsi Dong; Bingjie Li; Dan Lin; Qinghua Zhou; Depei Huang

doi:10.3389/fphar.2019.00230

Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing

Front Pharmacol. 2019 Mar 12:10:230. doi: 10.3389/fphar.2019.00230. eCollection 2019.

Authors

Jingsi Dong¹, Bingjie Li¹, Dan Lin¹, Qinghua Zhou¹, Depei Huang²

Affiliations

¹ Lung Cancer Center of West China Hospital, Sichuan University, Chengdu, China.
² The Medical Department, 3D Medicines Inc., Shanghai, China.

Abstract

The essence of precision medicine is to achieve the goal of "individualized treatment" through genotyping of patients and targeted therapy. At present, the pathogenic genes of non-small cell lung cancer (NSCLC) have been studied most thoroughly and targeted therapy based on genotyping has been the most successful. This paper focuses on the precision treatment of NSCLC based on genotyping, comparing gene detection methods and summarize the latest progress of NSCLC immunotherapy.

Keywords: ALK; EGFR; NSCLC; PD-L1; ROS1; immunotherapy; targeted therapy.

Publication types

Review